Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

HKG/1061 stock hub

HKG/1061 has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

HKG/1061is not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

1.8B

Hong Kong Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

HKG/1061

In the news

Latest news · HKG/1061

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E5.5

P25 11.7P50 18.9P75 41.4

Trailing P/E5.6

P25 10.7P50 17.9P75 38.5

ROE14

P25 -14.7P50 2P75 9.4

ROIC16.2

P25 -10.4P50 1.9P75 10.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All HKG/1061 market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

243

Groups with data

Currency

HKD

Showing 243 of 243 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	Cayman Islands
Country code	HK
Employees	1,426
Enterprise value	HKD 1.3B
Exchange	Hong Kong Stock Exchange
Financial currency	HKD
First seen	2026-05-10
Industry	Drug Manufacturers - Specialty & Generic
Isin	KYG312371035
Last refreshed	2026-05-10
Market cap	HKD 1.8B
Price	HKD 3.13
Price currency	HKD
Rev Per Employee	1,407,142.95x
Sector	Healthcare
Sic	2836
Symbol	hkg/1061
Website	https://www.essexbio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	17.92%
EV Earnings	4.2x
EV/EBIT	3.21x
EV/EBITDA	2.82x
EV/FCF	6.73x
EV/Sales	0.74x
FCF yield	11.2%
Forward P/E	5.49x
P/B ratio	0.74x
P/E ratio	5.58x
P/S ratio	0.98x
PE Ratio10 Y	7.75x
PE Ratio3 Y	7.01x
PE Ratio5 Y	6.35x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	22.98%
EBITDA Margin	25.8%
FCF margin	10.96%
Gross margin	89.2%
Gross Profit	HKD 1.6B
Gross Profit Growth	5.16%
Gross Profit Growth Q	10.45%
Gross Profit Growth3 Y	2.77%
Gross Profit Growth5 Y	2.74%
Net Income	HKD 318.1M
Net Income Growth	3.54%
Net Income Growth Q	3.28%
Net Income Growth Quarters	3%
Net Income Growth Years	3%
Net Income Growth3 Y	6.56%
Net Income Growth5 Y	4.44%
Pretax Margin	22.86%
Profit Margin	17.54%
Profit Per Employee	HKD 246,774
Profitable Years	22
ROA	8.05
Roa5y	7.94
ROCE	15.3
ROE	14.02
Roe5y	15.83
ROIC	16.18
Roic5y	17.85

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-0.89%
Cagr15y	10.86%
Cagr1y	-26.13%
Cagr20y	16.17%
Cagr3y	-1.93%
Cagr5y	-7.31%
Div CAGR10	18.8%
Div CAGR3	77.58%
Div CAGR5	22.87%
EPS Growth	5.49
EPS Growth Q	3.86
EPS Growth Quarters	3
EPS Growth Years	3
EPS Growth3 Y	7.64
EPS Growth5 Y	5.21
FCF Growth	-38.65%
FCF Growth Q	-27.07%
FCF Growth3 Y	-11.87%
FCF Growth5 Y	-5.84%
OCF Growth	-16.87%
OCF Growth Q	-22.37%
OCF Growth10 Y	0.23%
OCF Growth3 Y	-1.02%
OCF Growth5 Y	-0.07%
Revenue Growth	8.62x
Revenue Growth Q	11.41x
Revenue Growth Quarters	3x
Revenue Growth Years	1x
Revenue Growth3 Y	2.87x
Revenue Growth5 Y	3.04x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	HKD 0.56
Assets	HKD 3.5B
Cash	HKD 784.1M
Current Assets	HKD 1.6B
Current Liabilities	HKD 766.9M
Debt	HKD 346.9M
Debt EBITDA	HKD 0.73
Debt Equity	HKD 0.14
Debt FCF	HKD 1.74
Equity	HKD 2.4B
Interest Coverage	53.33
Liabilities	HKD 1.1B
Long Term Assets	HKD 1.9B
Long Term Liabilities	HKD 310.8M
Net Cash	HKD 437.2M
Net Cash By Market Cap	HKD 24.64
Net Cash Growth	17%
Net Debt EBITDA	HKD -0.93
Net Debt Equity	HKD -0.18
Net Debt FCF	HKD -2.2
Tangible Book Value	HKD 1.4B
Tangible Book Value Per Share	HKD 2.46
WACC	3.61

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	2.11
Inventory Turnover	2.08
Net Working Capital	HKD 138.2M
Quick ratio	1.92
Working Capital	HKD 853.2M
Working Capital Turnover	HKD 2.54

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	2.63%
Dividend Growth	16.67%
Dividend Growth Years	2%
Dividend per share	HKD 0.14
Dividend Years	18
Dividend Yield	4.47%
Ex Div Date	2026-05-28
Last Dividend	HKD 0.07
Payout Frequency	Semi-Annual
Payout Ratio	24.96%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-8.58%
1Y total return	-26.12%
200-day SMA	4.41
3Y total return	-5.68%
50-day SMA	3.61
50-day SMA vs 200-day SMA	50under200
5Y total return	-31.58%
All Time High	9.6
All Time High Change	-67.4%
All Time High Date	2018-03-15
All Time Low	0.05
All Time Low Change	5,664.27%
All Time Low Date	2003-04-24
ATR	0.14
Beta	-0.05
Beta1y	0.7
Beta2y	-0.31
Ch YTD	-16.98
High	3.23
High52	6.12
High52 Date	2025-08-18
High52ch	-48.86%
Low	3.11
Low52	3.06
Low52 Date	2026-05-05
Low52ch	2.29%
Ma50ch	-13.37%
Price vs 200-day SMA	-29.02%
RSI	34.24
RSI Monthly	42.65
RSI Weekly	29.1
Sharpe ratio	-0.7x
Sortino ratio	-0.88
Total Return	7.1%
Tr YTD	-16.98
Tr15y	369.32%
Tr1m	-13.54%
Tr1w	-3.1%
Tr3m	-24.76%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	HKD 416.8M
Operating Income Growth	7.33
Operating Income Growth Q	16.06
Operating Income Growth3 Y	9.05
Operating Income Growth5 Y	3.8
Operating margin	22.98

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	260,377,033%
Net Borrowing	144,427,510
Shares Insiders	54.08%
Shares Institutions	1.46%
Shares Out	567,006,000
Shares Qo Q	-0.01%
Shares Yo Y	-2.63%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	HKD 198.8M
Average Volume	379,200x
Bv Per Share	4.26
CAPEX	HKD -107.5M
Ch10y	-23.66
Ch15y	277.1
Ch1m	-13.54
Ch1w	-3.1
Ch1y	-28.05
Ch20y	1,390.5
Ch3m	-24.76
Ch3y	-14.01
Ch5y	-40.04
Ch6m	-29.19
Change	0%
Change From Open	-2.8
Close	3.13
Days Gap	2.88
Depreciation Amortization	51,122,327
Dollar Volume	181,540
Earnings Date	2026-03-23
EBIT	HKD 416.8M
EBITDA	HKD 467.9M
EPS	HKD 0.56
F Score	5
FCF	HKD 198.8M
FCF EV Yield	14.86x
FCF Per Share	HKD 0.35
Financing CF	62,097,662
Fiscal Year End	December
Founded	1,990
Goodwill	56,547,208
Graham Number	7.32926
Graham Upside	134.2
Income Tax	HKD 96.6M
Investing CF	-165,171,179
Is Primary Listing	1
Last Earnings Date	2026-03-23
Last Report Date	2025-12-31
Lynch Fair Value	HKD 2.8
Lynch Upside	-10.39
Ma150	4.08
Ma150ch	-23.27%
Ma20	3.25
Ma20ch	-3.81%
Net CF	225,563,572
Open	3.22
P FCF Ratio	8.93
P OCF Ratio	5.79
Payment Date	2026-06-12
Position In Range	16.67
Ppne	517,129,037
Price Date	2026-05-08
Price EBITDA	HKD 3.79
Ptbv Ratio	1.27
Relative Volume	0.14x
Revenue	1,813,807,257x
Tax By Revenue	5.32x
Tax Rate	23.29%
Tr20y	1,902.8%
Tr6m	-29.19%
Volume	58,000
Z Score	3.54

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

HKG/1061 dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+4.5%

$0.14 annual per share

Payout ratio

+25.0%

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

+22.9%

2 consecutive years of growth

Total shareholder yield

+7.1%

Next ex-dividend date: 2026-05-28

Performance

HKG/1061 stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns HKG/1061?

Insider, institutional, and short-interest positioning.

Institutional ownership

+1.5%

Share of float held by funds and institutions

Insider ownership

+54.1%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

-2.6%

Negative means the company is buying back shares.

Technical

HKG/1061 momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

34.2

Neutral momentum band

Price vs 200-day MA

-29.0%

50/200-day relationship not available

Beta (5Y)

-0.05

Less volatile than the market

Sharpe ratio

-0.70

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About HKG/1061

Hub-level FAQ points readers to the deeper analysis pages.

What is the current hkg/1061 stock rating?

hkg/1061 is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full hkg/1061 analysis?

The full report lives at /stocks/hkg/1061/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for hkg/1061?

The latest report frames hkg/1061 around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the hkg/1061 page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.